Compare Futu Holdings Ltd (FUTU) vs Mesoblast Limited (MESO) Price & Performance

Futu Holdings trades at $113.52, up 3.5% in the last session. The stock exhibits strong fundamentals with a P/E of 10.86 and net income margin of 42.92%, though technical indicators signal a bearish trend. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1 2026. The company's Moomoo platform continues expanding globally, with new partnerships and marketing initiatives driving user growth.

Outlook remains positive due to robust profitability and overseas expansion, but risks include ongoing securities class action lawsuits and competitive pressures. Analyst consensus is bullish with a 58.3% buy rating, projecting significant upside potential from current levels.

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.